Medicine

Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer

Source: 9th European Congress: Perspectives in Lung Cancer, Torino, Italy, March 14-15, 2008
Giorgio Scagliotti
Giorgio Scagliotti
Robert Pirker
Robert Pirker

GIORGIO SCAGLIOTTI, University of Turin
ROBERT PIRKER, Medical University of Vienna
A heated debate took place at the European Congress on Lung Cancer in Turin between Robert Pirker who is in favor of offering adjuvant chemotherapy to selected patients who have stage I non-small cell lung cancer, and Giorgio Scagliotti who took the opposite point of view. Peter Goodwin got them together and asked them to talk about the key issues influencing their views.

Download this interview

Similar Interviews

  • Audio Journal of Oncology 12.7, September 2004
  • Reporting from: - 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 - New England Journal

  • Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
  • Christian Manegold Nick Thatcher Christian Manegold, Heidelberg University Medical Center, Manheim Nick

  • Front Line Therapy in Non-Small Cell Lung Cancer
  • Nick Thatcher NICK THATCHER, Christie Hospital, Manchester There is a proven benefit in survival

    Post a comment